NATURECELL Co., Ltd.

As of March 31, 2026, NATURECELL Co., Ltd. carries a market capitalization of 1.12T, placing it among publicly traded companies globally. Its enterprise value stands at 1.11T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, NATURECELL Co., Ltd. has 64.44M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 53.82, and the price-to-book ratio stands at 17.68.

These figures are as of March 31, 2026. The EV/Sales ratio of 53.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.11T versus a market cap of 1.12T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, NATURECELL Co., Ltd. maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.08, indicating elevated leverage, while an interest coverage ratio of -4.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, NATURECELL Co., Ltd. posted a negative return on equity (ROE) of -4.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.48, reflecting losses generated across the asset base. The company generates approximately 238.12M in revenue per employee across its workforce of 87.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.13 indicates how many times NATURECELL Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, NATURECELL Co., Ltd. recorded 71.61M in income tax expense. The company reported a pretax loss of -2.67B and -2.74B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, NATURECELL Co., Ltd.'s stock has declined approximately 4.54% over the past 52 weeks. The 50-day moving average sits at 24,179.00, while the 200-day moving average is 22,814.55.

Over the twelve months ended March 31, 2026, NATURECELL Co., Ltd. generated 20.72B in revenue and converted that into -2.74B in net income, yielding earnings per share of -42.54. EBITDA reached -1.41B, while operating income came in at -3.34B.

As of March 31, 2026, NATURECELL Co., Ltd. holds 28.34B in cash and equivalents against 19.61B in total debt, resulting in a net debt position of -11.34B. Total book value stands at 63.09B, with working capital of 19.65B providing operational flexibility.

NATURECELL Co., Ltd. produced 965.52M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -15.18B in capital expenditures, free cash flow totaled -14.21B - equivalent to -220.60 per share.

Over the twelve months ended March 31, 2026, NATURECELL Co., Ltd. posted a gross margin of 48.59, reflecting its pricing power and cost economics. The operating margin of -16.14 and net profit margin of -13.23 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.52, meaning NATURECELL Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

NATURECELL Co., Ltd.'s most recent stock split took place on July 18, 2019 with a 685:733 split ratio.

As of March 31, 2026, NATURECELL Co., Ltd. has an Altman Z-Score of 27.43, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.